A prospective, open-label, observational study evaluating SYMLIN Rm [pramlintide acetate] injection use in insulin using patients with type 2 and type 1 diabetes following SYMLIN introduction into the marketplace.

Trial Profile

A prospective, open-label, observational study evaluating SYMLIN Rm [pramlintide acetate] injection use in insulin using patients with type 2 and type 1 diabetes following SYMLIN introduction into the marketplace.

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Jul 2014

At a glance

  • Drugs Pramlintide (Primary)
  • Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 30 Jun 2009 Actual end date (Apr 2008) added as reported by ClinicalTrials.gov.
    • 30 Jun 2009 Actual patient number (1297) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top